31 reports

  • North America Hepatitis Treatment B Market Overview
  • Global Hepatitis Treatment B Market- By Type

In United States largest number of drugs are into pipeline which is anticipated to propel the demand for hepatitis treatment in the U. S. market.

  • Hepatitis Treatment
  • World
  • Market Size
  • AbbVie Inc.
  • Bristol-Myers Squibb Company

Hepatitis C Therapies Market 2017-2027 ##.

  • Hepatitis Treatment
  • Therapy
  • Forecast
  • Market Shares
  • Market Size
  • Gilead Sciences Enters into Licensing Agreement with Hetero Labs

Sovaldi is indicated for the treatment of genotype ##, ##, ## or ## chronic hepatitis C virus (HCV) infection as a component of a combination antiviral treatment regimen.

  • Hepatitis Treatment
  • India
  • United States
  • Supply
  • Hetero Drugs Limited

Medicine; ##(##): ##-##.

  • Hepatitis Treatment
  • Market Size
  • AbbVie Inc.
  • Gilead Sciences, Inc.
  • Janssen Biotech, Inc.

One oral presentation, and one poster presentation, will disclose the most recent findings on the company' s novel drug TXL, for the treatment of chronic hepatitis B.

  • Hepatitis Treatment
  • Pharmaceutical
  • United States
  • Company
  • ContraVir Pharmaceuticals, Inc.

Global Market Study on Hepatitis C Treatment: Online Pharmacies Distribution Channel Segment Expected to Register the Fastest CAGR of ##. ##% During 2016 - 2024 ##.

  • Hepatitis Treatment
  • Therapy
  • World
  • Market Size

Under his leadership, Gilead has developed five medicines for the treatment of chronic hepatitis B and hepatitis C that have been used by nearly ## million people around the world.

  • Antiviral
  • Hepatitis
  • Hepatitis Treatment
  • United States
  • Gilead Sciences, Inc.
  • LICENSING AGREEMENTS

The agreement also permit the manufacture of sofosbuvir or ledipasvir in combination with other chronic hepatitis C medicines.

  • Hepatitis Treatment
  • Laboratory
  • India
  • Supply
  • Mylan Inc.
  • PRODUCT PROFILE - PREZCOBIX

HIV MEDICINE; ##: ##-##.

  • Hepatitis Treatment
  • East Asia
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • ViiV Healthcare Ltd.

Associate Professor of Medicine Division of Gastroenterology Department of Medicine, Siriraj Hospital, Mahidol University will be available for interviews in advance via teleconference or onsite.

  • Hepatitis
  • Hepatitis Treatment
  • Infectious Disease
  • World
  • GlaxoSmithKline plc

One unit refers to one test kit.

  • Clinical Trial
  • Hepatitis
  • Hepatitis Testing
  • Hepatitis Treatment
  • Abbott

CLINICAL TRIALS BY PHASE IN G## COUNTRIES HEPATITIS D THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY PHASE, 2017* HEPATITIS D THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY PHASE, 2017* HEPATITIS D THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY PHASE, 2017* Country Name Pha

  • Clinical Trial
  • Hepatitis Treatment
  • Pharmaceutical
  • World
  • Product Initiative
  • NOV 13, 2017: PHARMANIAGA, PHARCO AND DNDI SIGN AGREEMENT TO PROVIDE AFFORDABLE HEPATITIS C TREATMENT IN MALAYSIA
  • OCT 20, 2017: GILEAD ANNOUNCES PRESENTATION ON HARVONI AT THE LIVER MEETING 2017

Gilead Sciences, Inc. announced results from Phase ## and Phase ## studies of its approved medicines for chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infection, adding to the body of evidence supporting Gilead' s viral hepatitis

  • Hepatitis
  • Hepatitis Treatment
  • Research And Development
  • Therapy
  • Bristol-Myers Squibb Company

Sino' s principal products comprise hepatitis medicines, cardio-cerebral medicines, oncology medicines, orthopedic and anti-infectious medicines.

  • Antiviral
  • Hepatitis
  • Hepatitis Treatment
  • Therapy
  • Bristol-Myers Squibb Company

The American Journal of Medicine; ##(##): ##. e##-##.

  • Hepatitis Treatment
  • United States
  • World
  • Arbutus Biopharma Corporation
  • Gilead Sciences, Inc.

Global Hepatitis B Virus (HBV) Market: ##-Year Demand Forecast (2016-2025) ##.

  • Hepatitis Treatment
  • United States
  • World
  • Forecast
  • Gilead Sciences, Inc.

The American Journal of Medicine; ##(##): ##. e##-##.

  • Hepatitis Treatment
  • Japan
  • World
  • Arbutus Biopharma Corporation
  • Gilead Sciences, Inc.
  • Market drivers

IFN has been considered a cornerstone for hepatitis treatment since its launch.

  • Hepatitis Treatment
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.

Hepabig Injection Used for Prevention of Hepatitis B Relapse After Liver Transplantation (LT) GDCT## NCT##, Gastrointestinal Hepatitis B, Liver Cirrhosis Completed Phase IV Observational hepatitis B immune globulin (human) Seoul St.

  • Digestive System Disorder
  • Hepatitis Treatment
  • Medical Biotechnology
  • Pharmaceutical
  • World

Where relevant, CEAF medicines are funded in one of three ways: Group ##A: Drugs which are federally-funded and procured.

  • Hepatitis Treatment
  • Pharmaceutical
  • Brazil
  • Demand
  • GlaxoSmithKline plc
  • 3. Hepatitis C - Approved Drugs Sales & Forecast
  • The six main reasons for the high price-tags on promising new HCV drugs

This agreement allows Natco to expand access to these chronic hepatitis C medicines in ## developing countries.

  • Hepatitis Treatment
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.

Hepatitis C

4385 5000 3900

Annals of Internal Medicine, ##(##), ##−## < DOI> ##. ##/ M##-##< / DOI>.

  • Hepatitis Treatment
  • European Union
  • Japan
  • North America
  • United States

The American Journal of Medicine; ##(##): ##. e##-##.

  • Hepatitis Treatment
  • World
  • Forecast
  • Arbutus Biopharma Corporation
  • Gilead Sciences, Inc.

The drug is indicated for the treatment of chronic hepatitis C virus genotype ## infection.

  • Hepatitis Treatment
  • United States
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • 3. Hepatitis C - Approved Drugs Sales & Forecast to

Global sales of Victrelis, an oral medicine for the treatment of chronic hepatitis C, were US$ ## Million in 2013, a decline of ##% compared with 2012 including a ##% unfavorable effect from foreign exchange.

  • Hepatitis Treatment
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • Janssen Biotech, Inc.

GLOBAL HEPATITIS C VIRUS MARKET: THE COMPANY COULD BENEFIT FROM THE POTENTIAL GLOBAL HEPATITIS C VIRUS (HCV) MARKET.

  • Hepatitis Treatment
  • HIV AIDS
  • Pharmaceutical
  • Company
  • Gilead Sciences, Inc.
  • PRICE RESISTANCE: SOVALDI CASE STUDY

COUNCIL OF THE EUROPEAN UNION (2014) HIGH PRICE OF MEDICINES AGAINST HEPATITIS C.

  • Hepatitis Treatment
  • Hospital
  • Pharmaceutical
  • Europe
  • EFPIA company
  • REGIONAL ACCESS TO HEPATITIS C TREATMENTS VARIES IN SPAIN
  • CREATIVE TAXATION MAY BE USED TO MITIGATE BUDGETARY IMPACT OF PAYING FOR NEW HEPATITIS C THERAPIES

This means that hepatitis C virus (HCV) medicines that enable interferon-free treatment such as the Sovaldi/ ledipasvir combination can expect the G-BA to award them an assessment of considerable added benefit in GT- ## patients.

  • Hepatitis Treatment
  • Therapy
  • United States
  • Gilead Sciences, Inc.
  • Humana Inc.

Physician Views: Sovaldi revolutionises hepatitis C in the US, but what about uptake in the EU##?

  • Hepatitis
  • Hepatitis Treatment
  • Therapy
  • Europe
  • United States

What percentage of genotype ## hepatitis C patients they are currently warehousing (i. e. are diagnosed but not being treated)?

  • Antiviral
  • Hepatitis Treatment
  • Therapy
  • United States
  • Forecast